PRKRA

Across TCGA pan-cancer cohorts, PRKRA RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of PRKRA’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where PRKRA RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PRKRA is over-expressed in tumor, although a few such as KICH and KIRC show the opposite, repressed pattern.

LIHC, KICH, and HNSC are the cancer types where PRKRA tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRKRA RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	II,III,IV	+0.608	<.001	9	view →
KICH	Female	II,III,IV	−1.118	<.001	8	view →
HNSC	All	III,IV	+0.561	<.001	8	view →
LUAD	Male	II,III,IV	+0.406	<.001	8	view →
COAD	All	II,III,IV	+0.435	<.001	6	view →
CHOL	Male	All	+1.799	<.001	5	view →
READ	Male	All	+0.513	<.001	5	view →
LUSC	All	All	+0.411	<.001	4	view →
ESCA	All	All	+0.568	.004	2	view →
KIRC	Male	III,IV	−0.248	.023	2	view →
THCA	Female	All	−0.154	.042	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

PRKRA–LIHC

Open the LIHC breakdown →